A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Study: During Pandemic, High Blood Pressure Control Declined

Hypertension control and management worsened during the early months of the COVID-19 pandemic, according to a new analysis conducted at three large health systems, led by Cedars-Sinai investigators.

The study, published in the journal Hypertension, showed that during the first eight months of the pandemic, patients with hypertension measured their blood pressure less frequently, and when they did, their blood pressure readings were less healthy. The findings demonstrate the importance of ensuring ongoing access to healthcare with telemedicine and home blood pressure monitoring during emergencies.

“We had a unique opportunity to examine the pandemic’s impact on hypertension management among a large, diverse group of people from three major cities,” said Hiroshi Gotanda, MD, PhD, an assistant professor of Medicine at Cedars-Sinai. “Our analysis revealed similar patterns among participants from three different regions and a variety of racial, ethnic and socioeconomic backgrounds.”

Cedars-Sinai in Los Angeles led a group of investigators from Columbia University Irving Medical Center in New York City and Ochsner Health in New Orleans that analyzed the electronic health records of hypertensive adults followed by the three health systems.

To ensure participants had received continued care before the pandemic, investigators selected individuals whose health records included at least one primary care visit with a diagnosis of hypertension between August 2018 and January 2019 and another visit between February 2019 and January 2020. Participants had to be at least 18 years or older before the pandemic began in early 2020.

The investigators analyzed blood pressure measurements from the health records of 137,593 study participants. They compared pre-pandemic data (August 2018-January 2020) with data collected early in the pandemic (April 2020-November 2020) after stay-at-home orders were issued in California, Louisiana and New York. They excluded a transition period (February 2020-March 2020) after the pandemic began but before stay-at-home orders went into effect.

The analysis of the combined data found that 77.8% of participants had controlled blood pressure before the pandemic—a systolic reading of less than 140 mmHg over a diastolic reading of less than 90 mmHg. During the pandemic, the proportion of participants with controlled blood pressure decreased by 3.43 percentage points. A trend toward increasing control that had been observed before the stay-at-home orders flattened during the pandemic.

The investigators observed a small but significant increase in both systolic and diastolic blood pressure, after adjusting for participant characteristics and normal seasonal fluctuations. Systolic blood pressure increased by 1.79 mmHg and diastolic blood pressure increased by 1.30 mmHg during the pandemic compared with the pre-pandemic period.

“A small increase like that at a population level can have a significant effect, sometimes leading to an increase in heart attacks and stroke,” Gotanda said.

The number of blood pressure measurements began to decline during the pandemic transition period, dropping substantially early in the pandemic, then gradually increasing later in 2020. Disruptions in blood pressure monitoring likely contributed to the worsening in blood pressure control. The authors also suspected that effects of the early pandemic, such as decreased physical activity, disrupted sleep, unhealthy diets, increased stress and limited access to healthcare also could have played a role.

The review extended similar findings from previous research by studying data from a diverse group of participants and examining detailed clinical information to control for underlying issues that might impact study results, such as other chronic health conditions that could affect blood pressure outcomes.

“It is critical to increase access to healthcare, potentially through telemedicine and home blood pressure monitoring, to mitigate disruptions in care during future large-scale emergencies,” said senior author Teryl Nuckols, MD, MSHS, director of the Division of General Internal Medicine in the Cedars-Sinai Department of Medicine. “We want to avoid compounding the effects of widespread disasters by creating additional public health crises.”

The study was funded in part by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy